a16z Podcast/Novartis CEO Vasant Narasimhan on Transf...

How Novartis CEO unlocked $180 billion by breaking up a 250-year-old company

Vasant Narasimhan, CEO at Novartis at Novartis on

a16z Podcast · Novartis CEO Vasant Narasimhan on Transforming a...

“We spun off Alcon, now a standalone public company.”

5:26 / 5:45

We spun off Alcon, now a standalone public company. We spun off Sandoz, standalone public company. We sold our Roche steak. And so we sort of took this company that was a conglomerate, and we turned it into four companies. And it's not, of course, perfect math, but when you look at it, I mean, we unlocked almost a $180,000,000,000

About this clip

Novartis CEO Vasant Narasimhan explains how he transformed the pharmaceutical giant from a sprawling conglomerate into four focused companies through strategic spinoffs and divestitures. He details the spin-offs of Alcon and Sandoz, plus the sale of their Roche stake, which collectively unlocked nearly $180 billion in value.

Why this clip

Demonstrates a massive corporate transformation that unlocked extraordinary shareholder value through strategic portfolio simplification.

5:26 - 5:4518smarket insight

corporate-restructuring spinoffs value-creation

Share

More from this guest

Vasant Narasimhan

1 appearance · 6 clips

What they said next

How Novartis cut 6-month research from months to minutes using AI

35:13 - 20s · market insight

More from this episode

a16z Podcast · Vasant Narasimhan

Why Novartis had to break up its 250-year-old business model

Novartis CEO explains how running multiple business units with different economics forced strategic capital misallocation. He describes the tough trade-offs between optimizing their pharmaceutical business versus investing in generics and devices, ultimately leading to a major corporate restructuring.

6:34 - 7:0733s

capital-allocation corporate-restructuring business-focus

a16z Podcast · Vasant Narasimhan

How Novartis cut 6-month research from months to minutes using AI

Novartis CEO explains how their AI platform called Foundry has transformed their research capabilities, with 3,000 scientists now using AI models to extract data from their data lake in minutes instead of the six months it used to take. He describes this as an incredible leap in pharmaceutical research efficiency that took years to develop and implement.

35:13 - 35:3320s

ai-transformation data-analytics pharma-research

a16z Podcast · Vasant Narasimhan

Why the first AI-generated drug won't exist for another decade

Novartis CEO explains the harsh reality behind AI drug discovery hype - while everyone expects breakthrough results in two years, the first purely AI-generated drug candidate won't emerge for 8-10 years. He shares how Novartis is partnering with Isomorphic Labs to tackle previously 'undruggable' targets using AlphaFold technology.

33:18 - 33:4729s

ai-drug-discovery pharmaceutical-timelines undruggable-targets

a16z Podcast · Vasant Narasimhan

Novartis CEO explains the radical rethink that transformed a 250-year-old pharma giant

Novartis CEO Vasant Narasimhan describes the strategic decision to transform the company into a pure-play biopharmaceuticals business. He explains how they exited the consumer health business through a GSK joint venture and focused on specific therapeutic areas they believed would have the greatest impact.

4:55 - 5:2631s

corporate-transformation business-focus pharma-strategy

a16z Podcast · Vasant Narasimhan

If we could get more platforms in place where you could just go right into a particular disease without having to recontract and redo everything, you could generate the data a lot faster. Those kind of networks need to get scaled if the US wants to remain competitive.

Identifies a specific bottleneck (contracting/IRB reviews) that slows US drug development and connects it to national competitiveness. Practical insight into regulatory reform with clear competitive implications.

43:12 - 43:3322s

Similar clips from other shows

a16z Podcast

Private markets now capture 55% of value creation vs 12% decades ago

A dramatic shift has occurred in where tech value creation happens, with private markets now capturing 55% of value creation for recent IPOs compared to just 12% in previous decades. The speaker discusses how this trend has benefited private investors and highlights their portfolio of major private companies including SpaceX, OpenAI, Databricks, and Stripe.

20:37 - 21:1538s

private-markets value-creation ipos

From the blog

FrameworkOriginal Research

The 5 Clip Archetypes for VC Podcasts

10 min read

Want clips like this for your podcast?

We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.

Get 2 Episodes Clipped Free